Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial

被引：2

作者：

Abou-Alfa, G. ^{[1
]}

Borbath, I. ^{[2
]}

Cohn, A. ^{[3
]}

Goyal, L. ^{[4
]}

Lamarca, A. ^{[5
]}

Macarulla, T. ^{[6
,7
]}

Oh, D. ^{[8
]}

Roychowdhury, S. ^{[9
,10
]}

Sadeghi, S. ^{[11
]}

Shroff, R. ^{[12
]}

Howland, M. ^{[13
]}

Li, A. ^{[13
]}

Cho, T. ^{[13
]}

Pande, A. ^{[14
]}

Javle, M. ^{[14
]}

机构：

[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA

[2] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium

[3] Rocky Mt Canc Ctr, Denver, CO USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[6] Vall dHebron Univ Hosp, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Barcelona, Spain

[8] Seoul Natl Univ Hosp, Seoul, South Korea

[9] Ohio State Univ, Comprehens Canc Ctr, CLIA Canc Genom Lab, Columbus, OH 43210 USA

[10] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA

[11] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[12] Univ Arizona, Canc Ctr, Tucson, AZ USA

[13] QED Therapeut Inc, San Francisco, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1016/j.annonc.2020.04.226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-144

引用

页码：S136 / S137

页数：2